Regenlab USA sets $6 to $8 IPO range, targeting $17.5 million on Nasdaq
As seen on the 24/7 Wall St. homepage on October 27, 2026.
Regenlab USA sets $6-$8 IPO range for 2.5 million shares
Regenlab USA just put a number on its Nasdaq debut: $6 to $8 for 2.5 million shares, roughly $17.5 million at the midpoint with StoneX Financial running the book. The regenerative medicine company's first amendment moves it from placeholder to pricing territory, so the deal is close.
Continue ReadingShow less
Regenlab USA Inc. has amended its IPO registration with a price range of $6 to $8 per share. Moving from a placeholder filing to an actual price range signals the company is entering the final stretch before pricing.
The offering is slated for the Nasdaq, with StoneX Financial running the book as the underwriter responsible for drumming up investor demand and ultimately setting the final price within or around that range.
Sponsored
Twelve Tabs, One Thesis
Your Research Resets Every Morning
The quote page in one tab. Filings in another. A chart you rebuilt from scratch, a transcript you never went back and found, a screener whose settings you will redo next week. Nothing you built yesterday is still there.
AlphaSpace replaces all of it with one screen you arrange yourself. Earnings calendar, estimate versus actual, the call transcript, live news, your own charts, every panel wired to whatever ticker you click. Close the browser and it is all still sitting there tomorrow.
See What a Built View Looks Like →
(Sponsor)
An amended S-1 with a price range attached typically precedes the roadshow, during which management pitches institutional investors and gauges the demand needed to price and close the deal. Until a final price is set, the range remains subject to change.
Regenlab USA operates in regenerative medicine, and the offering is structured as a standard operating IPO funding the ongoing business rather than a financial engineering event. Final pricing will show how the market values the company out of the gate.
Mentioned: RGNA